<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04782505</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1248101</org_study_id>
    <nct_id>NCT04782505</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy Volunteers</brief_title>
  <official_title>A Open-label, Single-dose, Phase 1 Study to Compare and Evaluate the Safety and Pharmacokinetics According to the Dose of Camostat Mesylate in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and pharmacokinetics evaluation study according to the dose of camostat mesylate in&#xD;
      healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 13, 2021</start_date>
  <completion_date type="Anticipated">May 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Part1. Parallel, Part2. Crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of GBPA</measure>
    <time_frame>0-6 hr</time_frame>
    <description>Maximum blood concentration of GBPA (GUANIDINO BENZOYLOXY PHENYLACETIC ACID METHANESULFONATE) among observed blood concentrations at time points&#xD;
Immediately before administration of IP&#xD;
After administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of GBPA</measure>
    <time_frame>0-6 hr</time_frame>
    <description>Area under the blood concentration-time of GBPA (GUANIDINO BENZOYLOXY PHENYLACETIC ACID METHANESULFONATE) among observed blood concentrations at time points&#xD;
Immediately before administration of IP&#xD;
After administration</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWJ1248 100mg (100mg 1tab) PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWJ1248 200mg (100mg 2tab) PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWJ1248 300mg (100mg 3tab) PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWJ1248 100mg 2tab PO - Wash out - DWJ1248 200mg 1tab PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWJ1248 200mg 1tab PO - Wash out - DWJ1248 100mg 2tab PO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ1248</intervention_name>
    <description>Camostat mesylate Tablet from Daewoong</description>
    <arm_group_label>Cohort 1 (Part 1)</arm_group_label>
    <arm_group_label>Cohort 2 (Part 1)</arm_group_label>
    <arm_group_label>Cohort 3 (Part 1)</arm_group_label>
    <arm_group_label>Group A (Part 2)</arm_group_label>
    <arm_group_label>Group B (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults aged ≥ 19 and ≤ 55 years at screening&#xD;
&#xD;
          -  Subjects with body weight of ≥ 55.0 kg and ≤ 90.0 kg, and a body mass index (BMI) of ≥&#xD;
             18.0 and ≤ 29.9&#xD;
&#xD;
          -  Subjects who have no congenital or chronic disease and have no pathological symptoms&#xD;
             or findings as a result of an internal examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with current or prior history of a clinically significant hepatic, renal,&#xD;
             nervous, respiratory, gastrointestinal, endocrine, hematologic and oncologic,&#xD;
             urogenital, cardiovascular, musculoskeletal or psychiatric disorder&#xD;
&#xD;
          -  Subjects with symptoms of acute disease within 28 days prior to the scheduled first&#xD;
             administration date of IP&#xD;
&#xD;
          -  Subjects with a history of gastrointestinal diseases (e.g., Crohn's disease, ulcers,&#xD;
             etc.) or gastrointestinal resection (except simple appendectomy or hernia surgery)&#xD;
             that may affect the absorption of drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jang-Hee Hong, MD, PhD</last_name>
      <phone>82-42-280-6940</phone>
      <email>boniii@cnu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

